Merrimack Pharmaceuticals Inc (MACK)

5.61
0.10 1.70
NASDAQ : Health Care
Prev Close 5.51
Open 5.52
Day Low/High 5.51 / 5.69
52 Wk Low/High 5.02 / 11.18
Volume 1.12M
Avg Volume 1.72M
Exchange NASDAQ
Shares Outstanding 127.73M
Market Cap 702.49M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Merrimack Pharmaceuticals (MACK) Weak On High Volume Today

Merrimack Pharmaceuticals (MACK) Weak On High Volume Today

Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a weak on high relative volume candidate

RSI Alert: Merrimack Pharmaceuticals (MACK) Now Oversold

RSI Alert: Merrimack Pharmaceuticals (MACK) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of MACK August 19th Options Trading

First Week of MACK August 19th Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the August 19th expiration.

Merrimack To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer

Merrimack To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer

Oral presentation on Phase 3 NAPOLI-1 data will highlight the effects of the ONIVYDE® (irinotecan liposome injection) regimen on quality of life for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy

MACK: Insiders vs. Shorts

MACK: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Merrimack Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 10.23 "days to cover" versus the median component at 5.75.

Merrimack Pharmaceuticals (MACK) Is Weak On High Volume Today

Merrimack Pharmaceuticals (MACK) Is Weak On High Volume Today

Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a weak on high relative volume candidate

Final Analysis Of First-in-Human Phase 1 Study Of MM-151 Shows Positive Clinical Activity In Multiple Solid Tumor Types, Including Colorectal Cancer

Final Analysis Of First-in-Human Phase 1 Study Of MM-151 Shows Positive Clinical Activity In Multiple Solid Tumor Types, Including Colorectal Cancer

Objective response observed in 21 percent of evaluable patients in the metastatic colorectal cancer (CRC) cohort; reduction in tumor size observed in 54 percent of patients in same cohort

These 7 Stocks Under $10 Are About to Break Out

These 7 Stocks Under $10 Are About to Break Out

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

More Picks for a Rough Market

Let's look at other attractively valued bets in what is at least a slightly overbought market overall.

Merrimack Announces A Leading-edge Biomarker-Selected, Multi-Arm Basket Trial That Matches Patients With Most Appropriate Combination Regimens

Merrimack Announces A Leading-edge Biomarker-Selected, Multi-Arm Basket Trial That Matches Patients With Most Appropriate Combination Regimens

Multiple biomarkers will be used to match patients to appropriate novel combinations of investigational therapies based on their cancer's molecular signature

Merrimack To Present On Extensive Oncology Pipeline At The 2016 American Society Of Clinical Oncology Annual Meeting

Merrimack To Present On Extensive Oncology Pipeline At The 2016 American Society Of Clinical Oncology Annual Meeting

Final results of Phase I study of MM-151, an oligoclonal anti-EGFR antibody, in patients with refractory solid tumors to be presented

Merrimack Presents Expanded Analysis From Seribantumab (MM-121) Phase 2 Breast Cancer Study At The AACR Precision Medicine Series

Merrimack Presents Expanded Analysis From Seribantumab (MM-121) Phase 2 Breast Cancer Study At The AACR Precision Medicine Series

Analysis of Overall Survival secondary endpoint of the full population indicates that seribantumab decreased risk of death by more than 50% in HER2-negative, hormone receptor positive breast cancer patients

Short Interest Declines 19.6% For MACK

Short Interest Declines 19.6% For MACK

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 5,101,255 share decrease in total short interest for Merrimack Pharmaceuticals Inc. , to 20,975,495, a decrease of 19.56% since 04/15/2016.

Looking Back at Biotech and Housing Small-Caps

I continue to like RLYP, TPH and LGIH.

4 Possible Biotech M&A Targets

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.

Commit To Purchase Merrimack Pharmaceuticals At $6, Earn 15.8% Annualized Using Options

Commit To Purchase Merrimack Pharmaceuticals At $6, Earn 15.8% Annualized Using Options

Investors eyeing a purchase of Merrimack Pharmaceuticals Inc. stock, but cautious about paying the going market price of $7.30/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Merrimack Unveils Its Latest Antibody Directed Nanotherapeutic, MM-310, At The 2016 AACR Annual Meeting

Merrimack Unveils Its Latest Antibody Directed Nanotherapeutic, MM-310, At The 2016 AACR Annual Meeting

- MM-310 is an antibody directed nanotherapeutic (ADN) targeting the EphA2 receptor, which tumor surveys suggest is present in 50-100% of major tumor types including prostate, ovarian, bladder, gastric and lung cancers

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

Merrimack Pharmaceuticals (MACK) Highlighted As Weak On High Volume

Merrimack Pharmaceuticals (MACK) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a weak on high relative volume candidate

Don't Throw This Biotech 'Baby' Out With the Bathwater

Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Merrimack Announces Inclusion Of ONIVYDE® (irinotecan Liposome Injection) As A Category 1 Treatment Option In The 2016 NCCN Guidelines For Pancreatic Adenocarcinoma

Merrimack Announces Inclusion Of ONIVYDE® (irinotecan Liposome Injection) As A Category 1 Treatment Option In The 2016 NCCN Guidelines For Pancreatic Adenocarcinoma

Updated guidelines recognize the ONIVYDE regimen as a standard-of-care for treatment of patients with post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals (MACK) Is Today's Perilous Reversal Stock

Merrimack Pharmaceuticals (MACK) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a "perilous reversal" (up big yesterday but down big today) candidate